Brivaracetam oral solution
Sponsors
UCB Biopharma SRL
Conditions
Childhood Absence EpilepsyJuvenile Absence Epilepsy
Phase 3
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
CompletedNCT05109234
Start: 2022-03-30End: 2025-03-18Updated: 2025-10-22
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Active, not recruitingNCT06315322
Start: 2024-07-10End: 2029-11-16Updated: 2026-08-27